Clostridioides difficile Infection in Liver Cirrhosis: A Concise Review
- PMID: 35711246
- PMCID: PMC9197604
- DOI: 10.1155/2022/4209442
Clostridioides difficile Infection in Liver Cirrhosis: A Concise Review
Abstract
Clostridium difficile is a Gram-positive bacillus with fecal-oral transmission and is currently one of the most common nosocomial infections worldwide, which was renamed Clostridioides difficile in 2016. Clostridioides difficile infection (CDI) is a prevalent infection in cirrhosis and negatively affects prognosis. This study aimed to provide a concise review with clinical practice implications. The prevalence of CDI in cirrhotic patients increases, while the associated mortality decreases. Multiple groups of risk factors increase the likelihood of CDI in patients with cirrhosis, such as antibiotic use, the severity of cirrhosis, some comorbidities, and demographic aspects. Treatment in the general population is currently described in the latest guidelines. In patients with cirrhosis, rifaximin and lactulose have been shown to reduce CDI risk due to their modulatory effects on the intestinal flora, although conflicting results exist. Fecal microbiota transplantation (FMT) as a treatment for the second or subsequent CDI recurrences has demonstrated a good safety and efficacy in cirrhosis and CDI. Future validation in more prospective studies is needed. Screening of asymptomatic patients appears to be discouraged for the prevention currently, with strict hand hygiene and cleaning of the ward and medical equipment surfaces being the cornerstone of minimizing transmission.
Copyright © 2022 Yuanbin Liu and Mingkai Chen.
Conflict of interest statement
The authors declare no conflicts of interest in this study.
Figures

Similar articles
-
Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis.Clin Gastroenterol Hepatol. 2021 Aug;19(8):1627-1634. doi: 10.1016/j.cgh.2020.06.051. Epub 2020 Jul 6. Clin Gastroenterol Hepatol. 2021. PMID: 32645451 Free PMC article.
-
Disordered Intestinal Microbial Communities During Clostridioides difficile Colonization and Subsequent Infection of Hepatic Cirrhosis Patients in a Tertiary Care Hospital in China.Front Cell Infect Microbiol. 2022 Apr 1;12:825189. doi: 10.3389/fcimb.2022.825189. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35433508 Free PMC article.
-
Fecal Microbiota Transplantation for Clostridioides difficile in High-Risk Older Adults Is Associated with Early Recurrence.Dig Dis Sci. 2020 Dec;65(12):3647-3651. doi: 10.1007/s10620-020-06147-z. Epub 2020 Feb 20. Dig Dis Sci. 2020. PMID: 32078714
-
Systematic Review with Meta-Analysis: Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile.Dig Dis Sci. 2022 Mar;67(3):978-988. doi: 10.1007/s10620-021-06908-4. Epub 2021 Mar 22. Dig Dis Sci. 2022. PMID: 33748913
-
How to: prophylactic interventions for prevention of Clostridioides difficile infection.Clin Microbiol Infect. 2021 Dec;27(12):1777-1783. doi: 10.1016/j.cmi.2021.06.037. Epub 2021 Jul 8. Clin Microbiol Infect. 2021. PMID: 34245901 Review.
Cited by
-
Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions.World J Gastroenterol. 2022 Nov 7;28(41):5910-5930. doi: 10.3748/wjg.v28.i41.5910. World J Gastroenterol. 2022. PMID: 36405106 Free PMC article. Review.
-
Membrane Vesicles of Toxigenic Clostridioides difficile Affect the Metabolism of Liver HepG2 Cells.Antioxidants (Basel). 2023 Mar 27;12(4):818. doi: 10.3390/antiox12040818. Antioxidants (Basel). 2023. PMID: 37107193 Free PMC article.
-
Clostridioides difficile infection in patients with nonalcoholic fatty liver disease-current status.World J Hepatol. 2023 Feb 27;15(2):208-215. doi: 10.4254/wjh.v15.i2.208. World J Hepatol. 2023. PMID: 36926243 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources